Spots Global Cancer Trial Database for Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Official Title: Osimertinib With Chemotherapy as First-line Therapy for Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-Small Cell Lung Cancer (NSCLC): A Multicentre, Observational Study (FOREFRONT)

Study ID: NCT06376084

Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Interventions

Study Description

Brief Summary: To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS.

Detailed Description: The objectives of this study are to assess the effectiveness and safety of Osimertinib combined with chemotherapy in a real-world setting in patients with locally advanced or metastatic, EGFR mutation-positive NSCLC.